Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV

Phase II

This study is ongoing, but not recruiting participants

This research study of an investigational synthetic DNA vaccine is enrolling women with CIN 2/3 or CIN 3 associated with HPV type 16 or HPV type 18. The goal is to evaluate whether the cervical lesions will regress to CIN 1 or less within nine months after the first treatment in this study. A secondary goal will be to assess the clearance of HPV 16 and HPV 18.

Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation with CELLECTRA®-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 with Documented HPV 16 or 18

HPV-003 Clinical Research Study

VGX-3100

For more information please go to the study protocol.





Acute myeloid leukemia and chronic myeloid leukemia

Phase II

The study is not currently recruiting new subjects due to an interruption in sponsor funding. Efforts are under way to re-establish funding, however, the study is currently on hold pending the outcome of these refunding efforts. There have been no safety concerns identified during the study.

This study is evaluating a DNA vaccine against AML and CML, specifically: 1) Molecular response following p.DOM-epitope DNA vaccination in patients with CML (BCR-ABL, WT1) and AML (WT1) 2) Time to disease progression; two year survival rate (patients with AML) 3) Correlation of molecular responses with immunological responses.

WT1 Immunity via DNA Fusion Gene Vaccination in Hematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (WIN)

RHMCAN-0700 Clinical Research Study

Wilms' tumor gene 1 (WT1) DNA vaccine

University of Southampton

For more information please go to the study protocol.